## Title:

Structural and mechanistic basis for G $\beta\gamma$ -mediated activation of phosphoinositide 3-kinase  $\gamma$ 

## Authors

Chun-Liang Chen<sup>1</sup>, Ramizah Sabri<sup>1</sup>, Sandeep K. Ravala<sup>1</sup>, Yu-Chen Yen<sup>1</sup>, Thomas Klose<sup>1</sup>, Qing Deng<sup>1</sup> and John J. G. Tesmer<sup>1</sup>

## Affiliations

1 Department of Biological Sciences, Purdue University, West Lafayette, IN, 47906

## Abstract

Phosphoinositide 3-kinase  $\gamma$  (PI3K $\gamma$ ) converts PIP<sub>2</sub> to PIP<sub>3</sub> in a key step of leukocyte chemotaxis. However, it is also highly expressed in some cancers where it contributes to metastasis, particularly in prostate, breast, and pancreatic cancer. PI3Kg contains a catalytic subunit (p110 $\gamma$ ) and a regulatory subunit (p101), and activation of PI3Ky is coordinately regulated by  $G\beta\gamma$  subunits and Ras, which are activated downstream of G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs), respectively. However, detailed molecular mechanisms underlying the G $\beta\gamma$ - and Ras-mediated activation of PI3K $\gamma$  remain unclear. In this study, we hypothesize that  $G\beta\gamma$  binding triggers conformational changes of PI3K $\gamma$ , leading to its activation. To test the hypothesis, we purified functional PI3K $\gamma$  that demonstrates its G $\beta\gamma$ -dependent activation in the *in vitro* kinase assays. We then determined the cryo-EM structure of native PI3Kγ (3.0 Å resolution) and various cryo-EM reconstructions of the PI3Ky-G $\beta$ y complexes (3.5-3.6 Å resolution), revealing two distinct G $\beta$ y binding sites, one on the helical domain of  $p110\gamma$  and one on the C-terminal domain of p101. Conformational changes have been observed upon  $G\beta\gamma$  binding to PI3Ky, and key residues that were identified can be associated to allosteric activation. In vitro kinase assays and rescue experiments in Zebrafish are consistent with these findings, which allow for functional investigation of  $G\beta\gamma$ -mediated activation mechanisms and will potentially aid in future drug development targeting PI3Ky for selective cancer therapeutics, based on its unique responsiveness to  $G_{\beta\gamma}$ among PI3K isozymes.